Rationale and design of the HepZero study: a prospective, multicenter, international, open, randomized, controlled clinical study with parallel groups comparing heparin-free dialysis with heparin-coated dialysis membrane (Evodial) versus standard care: study protocol for a randomized controlled trial

Patrick Rossignol, Marc Dorval, Renaud Fay, Joan Fort Ros, Nathalie Loughraieb, Frédérique Moureau, Maurice Laville, Patrick Rossignol, Marc Dorval, Renaud Fay, Joan Fort Ros, Nathalie Loughraieb, Frédérique Moureau, Maurice Laville

Abstract

Background: Anticoagulation for chronic dialysis patients with contraindications to heparin administration is challenging. Current guidelines state that in patients with increased bleeding risks, strategies that can induce systemic anticoagulation should be avoided. Heparin-free dialysis using intermittent saline flushes is widely adopted as the method of choice for patients at risk of bleeding, although on-line blood predilution may also be used. A new dialyzer, Evodial (Gambro, Lund, Sweden), is grafted with unfractionated heparin during the manufacturing process and may allow safe and efficient heparin-free hemodialysis sessions. In the present trial, Evodial was compared to standard care with either saline flushes or blood predilution.

Methods: The HepZero study is the first international (seven countries), multicenter (10 centers), randomized, controlled, open-label, non-inferiority (and if applicable subsequently, superiority) trial with two parallel groups, comprising 252 end-stage renal disease patients treated by maintenance hemodialysis for at least 3 months and requiring heparin-free dialysis treatments. Patients will be treated during a maximum of three heparin-free dialysis treatments with either saline flushes or blood predilution (control group), or Evodial. The first heparin-free dialysis treatment will be considered successful when there is: no complete occlusion of air traps or dialyzer rendering dialysis impossible; no additional saline flushes to prevent clotting; no change of dialyzer or blood lines because of clotting; and no premature termination (early rinse-back) because of clotting.The primary objectives of the study are to determine the effectiveness of the Evodial dialyzer, compared with standard care in terms of successful treatments during the first heparin-free dialysis. If the non-inferiority of Evodial is demonstrated then the superiority of Evodial over standard care will be tested. The HepZero study results may have major clinical implications for patient care.

Trial registration: ClinicalTrials.gov NCT01318486.

Figures

Figure 1
Figure 1
Study flow-chart.
Figure 2
Figure 2
Visual clotting scale.

References

    1. Mujais SK, Chimeh H. Heparin free hemodialysis using heparin coated hemophan. ASAIO J. 1996;42:M538–M541. doi: 10.1097/00002480-199609000-00044.
    1. McGill RL, Blas A, Bialkin S, Sandroni SE, Marcus RJ. Clinical consequences of heparin-free hemodialysis. Hemodial Int. 2005;9:393–398. doi: 10.1111/j.1542-4758.2005.01158.x.
    1. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association Guideline Practice Guideline. Section v. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant. 2002;17(Suppl 7):63–71.
    1. Casati S, Graziani G, Ponticelli C. Hemodialysis without anticoagulants in patients with high bleeding risk. Int J Artif Organs. 1982;5:233–236.
    1. Hathiwala S. Dialysis without anticoagulation. Int J Artif Organs. 1983;6:64–66.
    1. Casati S, Moia M, Graziani G, Cantaluppi A, Citterio A, Mannucci PM, Ponticelli C. Hemodialysis without anticoagulants: Efficiency and hemostatic aspects. Clin Nephrol. 1984;21:102–105.
    1. Agresti J, Conroy JD, Olshan A, Conroy JF, Schwartz A, Brodsky I, Krevolin L, Chinitz J. Heparin-free hemodialysis with cuprophan hollow fiber dialyzers by a frequent saline flush, high blood flow technique. Trans Am Soc Artif Intern Organs. 1985;31:590–594.
    1. Sanders PW, Taylor H, Curtis JJ. Hemodialysis without anticoagulation. Am J Kidney Dis. 1985;5:32–35.
    1. Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ. Heparin free dialysis: Comparative data and results in high risk patients. Kidney Int. 1987;31:1351–1355. doi: 10.1038/ki.1987.149.
    1. Preuschof L, Keller F, Seemann J, Offermann G. Heparin-free hemodialysis with prophylactic change of dialyser and blood lines. Int J Artif Organs. 1988;11:255–258.
    1. Keller F, Seemann J, Preuschof L, Offermann G. Risk factors of system clotting in heparin-free haemodialysis. Nephrol Dial Transplant. 1990;5:802–807. doi: 10.1093/ndt/5.9.802.
    1. Kim YG. Anticoagulation during haemodialysis in patients at high-risk of bleeding. Nephrology (Carlton) 2003;8(Suppl):S23–S27.
    1. Cheng YL, Yu AW, Tsang KY, Shah DH, Kjellstrand CM, Wong SM, Lau WY, Hau LM, Ing TS. Anticoagulation during haemodialysis using a citrate-enriched dialysate: a feasibility study. Nephrol Dial Transplant. 2011;26:641–646. doi: 10.1093/ndt/gfq396.
    1. Yixiong Z, Jianping N, Yanchao L, Siyuan D. Low dose of argatroban saline flushes anticoagulation in hemodialysis patients with high risk of bleeding. Clin Appl Thromb Hemost. 2010;16:440–445. doi: 10.1177/1076029609334628.
    1. Stamatiadis DN, Helioti H, Mansour M, Pappas M, Bokos JG, Stathakis CP. Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe and efficient. Clin Nephrol. 2004;62:29–34.
    1. Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transplant. 2003;18:2097–2104. doi: 10.1093/ndt/gfg272.
    1. Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Chanard J. Assessment of the heparin-binding an69 st hemodialysis membrane: Ii. Clinical studies without heparin administration. ASAIO J. 2005;51:348–351. doi: 10.1097/01.mat.0000169121.09075.53.
    1. Kessler M, Gangemi C, Gutierrez Martones A, Lacombe JL, Krier-Coudert MJ, Galland R, Kielstein J, Moureau F, Loughraieb N. Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: A prospective proof-of-concept study. Hemodial Int. 2013;17:282–293. doi: 10.1111/j.1542-4758.2012.00733.x.
    1. Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis. 2007;49:642–649. doi: 10.1053/j.ajkd.2007.02.001.
    1. Kodras K, Benesch T, Neumann I, Haas M. Comparison of two dialysers (an69st vs. Fx100) for heparin-free dialysis in patients with oral anticoagulation. Blood Purif. 2008;26:226–230. doi: 10.1159/000118846.
    1. Richtrova P, Rulcova K, Mares J, Reischig T. Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs. 2011;35:83–88. doi: 10.1111/j.1525-1594.2010.01038.x.
    1. Morena M, Jaussent I, Chalabi L, Bargnoux AS, Dupuy AM, Badiou S, Rakic C, Thomas M, Canaud B, Cristol JP. Biocompatibility of heparin-grafted hemodialysis membranes: Impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int. 2010;14:403–410. doi: 10.1111/j.1542-4758.2010.00494.x.
    1. Sanchez-Canel JJ, Pons-Prades R, Salvetti ML, Seores A, Vazquez M, Perez-Alba A, Tamarit E, Calvo-Gordo C, Villatoro J. Evaluation of coagulation and anti-xa factor when using a heparin-coated an69st(r) dialyser. Nefrologia. 2012;32:605–612.
    1. Lohr JW, Schwab SJ. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol. 1991;2:961–975.
    1. Ziai F, Benesch T, Kodras K, Neumann I, Dimopoulos-Xicki L, Haas M. The effect of oral anticoagulation on clotting during hemodialysis. Kidney Int. 2005;68:862–866. doi: 10.1111/j.1523-1755.2005.00468.x.
    1. Wright S, Steinwandel U, Ferrari P. Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology (Carlton) 2011;16:396–402. doi: 10.1111/j.1440-1797.2010.01421.x.
    1. Bertrand D, Hanoy M, Le Roy F, Godin M. Comparaison de deux modalités de dialyse sans héparine à la technique de reference des rincages: Abstract presented at the sfd annual congress. Nephrol Ther. 2010;6:281–299.
    1. Guéry B, Servais A, Harrami E, Bererhi L, Zins B, Lesavre P, Touam M, Alberti C, Joly D. Hémodialyse sans héparinisation systemique: Comparaison de trois protocoles: Abstract presented at sfd annual congress. Nephrol Ther. 2010;6:281–299.
    1. Newcombe RG. Estimating the difference between differences: Measurement of additive scale interaction for proportions. Stat Med. 2001;20:2885–2893. doi: 10.1002/sim.925.
    1. Kozik-Jaromin J, Nier V, Heemann U, Kreymann B, Bohler J. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant. 2009;24:2244–2251. doi: 10.1093/ndt/gfp017.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel